About Predictive Oncology
Predictive Oncology is a company based in Eagan (United States) founded in 2002 was acquired by Renovaro in January 2024.. Predictive Oncology has raised $43 million across 9 funding rounds from investors including Draper Triangle, Longitude Capital and Adams Capital Management. The company has 24 employees as of December 31, 2024. Predictive Oncology has completed 5 acquisitions, including BioDtech, Helomics and Quantitative Medicine. Predictive Oncology offers products and services including AI/ML Platform, 3D Tumor Models, and Clinical Testing Services. Predictive Oncology operates in a competitive market with competitors including Owkin, Formation Bio, AbSci, BigHat and Benchsci, among others.
- Headquarter Eagan, United States
- Employees 24 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Predictive Oncology Inc.
-
Annual Revenue
$1.62 M-0.24as on Dec 31, 2024
-
Net Profit
$-12.2 M12.75as on Dec 31, 2024
-
EBITDA
$-10.24 M10.09as on Dec 31, 2024
-
Total Equity Funding
$43 M (USD)
in 9 rounds
-
Latest Funding Round
$50.77 M (USD), Post-IPO
Oct 07, 2025
-
Investors
Draper Triangle
& 6 more
-
Employee Count
24
as on Dec 31, 2024
-
Investments & Acquisitions
BioDtech
& 4 more
-
Acquired by
Renovaro
(Jan 06, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Predictive Oncology
Predictive Oncology is a publicly listed company on the NASDAQ with ticker symbol POAI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Predictive Oncology
Predictive Oncology offers a comprehensive portfolio of products and services, including AI/ML Platform, 3D Tumor Models, and Clinical Testing Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform pairs AI with tumor samples to predict drug responses.
Models mimic human tumors for accurate drug response testing.
Services provide tumor drug-response and biomarker testing.
Unlock access to complete
Unlock access to complete
Funding Insights of Predictive Oncology
Predictive Oncology has successfully raised a total of $43M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50.77 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $50.8M
-
First Round
First Round
(11 Nov 2008)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Post-IPO - Predictive Oncology | Valuation |
investors |
|
| Aug, 2025 | Amount | Post-IPO - Predictive Oncology | Valuation |
investors |
|
| May, 2022 | Amount | Post-IPO - Predictive Oncology | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Predictive Oncology
Predictive Oncology has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Draper Triangle, Longitude Capital and Adams Capital Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location | |
|
Early-stage VC investments are made in US tech companies.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Predictive Oncology
Predictive Oncology has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include BioDtech, Helomics and Quantitative Medicine. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Tumor-specific in vitro 3D models are supplied for drug development.
|
2014 | ||||
|
Quantitative Medicine is a biomedical analytics and computational biology company.
|
2012 | ||||
|
Kits and services for protein solubility assessment are provided.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Predictive Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Predictive Oncology Comparisons
Competitors of Predictive Oncology
Predictive Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Owkin, Formation Bio, AbSci, BigHat and Benchsci, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An agentic AI platform is developed for biomedical research insights.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for various diseases
|
|
| domain | founded_year | HQ Location |
AI-based technology is used for recombinant protein production in therapeutics.
|
|
| domain | founded_year | HQ Location |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| domain | founded_year | HQ Location |
AI platform used for extracting antibody data from scientific papers.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Predictive Oncology
Frequently Asked Questions about Predictive Oncology
When was Predictive Oncology founded?
Predictive Oncology was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Where is Predictive Oncology located?
Predictive Oncology is headquartered in Eagan, United States. It is registered at Eagan, Minnesota, United States.
Who is the current CEO of Predictive Oncology?
Carl Schwartz is the current CEO of Predictive Oncology.
Is Predictive Oncology a funded company?
Predictive Oncology is a funded company, having raised a total of $43M across 9 funding rounds to date. The company's 1st funding round was a Post-IPO of $2.3M, raised on Nov 11, 2008.
How many employees does Predictive Oncology have?
As of Dec 31, 2024, the latest employee count at Predictive Oncology is 24.
What is the annual revenue of Predictive Oncology?
Annual revenue of Predictive Oncology is $1.62M as on Dec 31, 2024.
What does Predictive Oncology do?
Predictive Oncology was founded in 2002 and is headquartered in Eagan, United States. Operations focus on the healthcare sector, where an AI-driven platform supports cancer diagnostics and precision medicine development. Multi-omics data analysis and diagnostic tools are integrated to aid treatment planning and decision-making processes. Assessment and inventory systems for personalized therapies are also maintained through this technology.
Who are the top competitors of Predictive Oncology?
Predictive Oncology's top competitors include Owkin, Formation Bio and XtalPi.
What products or services does Predictive Oncology offer?
Predictive Oncology offers AI/ML Platform, 3D Tumor Models, and Clinical Testing Services.
Is Predictive Oncology publicly traded?
Yes, Predictive Oncology is publicly traded on NASDAQ under the ticker symbol POAI.
How many acquisitions has Predictive Oncology made?
Predictive Oncology has made 5 acquisitions, including BioDtech, Helomics, and Quantitative Medicine.
Who are Predictive Oncology's investors?
Predictive Oncology has 7 investors. Key investors include Draper Triangle, Longitude Capital, Adams Capital Management, Quaker Partners Management, and Birchmere Ventures.
What is Predictive Oncology's ticker symbol?
The ticker symbol of Predictive Oncology is POAI on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.